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ABSTRACT
Objective: To assess the prognostic value of the percentage of positive fragments (PPF) in
biopsies from patients with localized prostate cancer (PCa) undergoing radical prostatectomy.
Materials and Methods: During the period from March 1991 to November 2000, 440 pa-
tients were selected. Cases receiving neoadjuvant or adjuvant hormone therapy, or adjuvant radio-
therapy, were excluded, as were cases presenting Gleason scores higher than 6 at biopsy. PPF was
defined as the total number of fragments divided by the total number of biopsy fragments times 100.
This variable was initially divided into categories from 0 to 25%, 25.1% to 50%, 50.1 to 75% and
75% to 100%. During the postoperative period, patients were assessed every 2 months for 1 year, then
every 6 months for 5 years, and then yearly. Biochemical recurrence was defined as serum PSA higher
than or equal to 0.4 ng/mL. Median follow-up was 60 months.
Results: One hundred and nine (24.8%) of the 440 patients under study had biochemical
recurrence. In the univariate analysis, PPF significantly influenced disease-free survival (log-rank, p
< 0.001), and patients with PPF between 75 and 100% presented a risk of a biochemical recurrence of
the disease 3 times higher than patients with PPF between 0 and 25% (p < 0.001). After the Cox
regression analysis, both serum PSA (p = 0.001) and PPF (p < 0.001) showed to be independent
predictive factors for disease-free survival following surgery.
Conclusion: PPF measurement in biopsy is a simple and practical method, which should be
routinely used as a predictive factor for biochemical recurrence in patients with PCa presenting Gleason
scores between 2 and 6.
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INTRODUCTION
Currently, 50% of patients with localized
prostate cancer (PCa) are treated with radical pros-
tatectomy (1); however, the finding of organ-confined
cancer in the surgical specimen does not guarantee
postoperative biochemical control of the disease.
Thus, approximately 30% of patients undergoing radi-
cal prostatectomy will present an increase in prostate
specific antigen (PSA) on long term (2).
Currently, the biopsy’s histological grade along
with the PSA and clinical staging (American Joint
Committee on Cancer - AJCC, 1992) are the most fre-
quently used pre-operative prognostic variables for
identifying patients with a higher risk of presenting
organ-confined disease in the surgical specimen (3).
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More recently, studies have demonstrated that
greater detailing of pathological data obtained from
prostate biopsy, in addition to merely identifying can-
cer and assessing its histological grade, can improve
diagnostic accuracy in these patients. Thus, the per-
centage of fragments with cancer (PPF) has been
widely used as a predictive factor for tumor volume,
extracapsular extension, invasion of seminal vesicle,
lymph nodal involvement and percentage of fragments
with Gleason score 4 and 5 (4-8).
PPF has been used as well to predict postop-
erative risk of biochemical recurrence (9-14). Presti
et al. (9) defined that Gleason score for biopsy and
PPF are the most important predictive factors for post-
operative biochemical recurrence. D’Amico et al. (10)
divided patients into risk groups based on classic pa-
rameters (PSA, Gleason score and clinical staging),
and during a 4-year follow-up, observed that, among
patients from the low risk group, 25% and 10% had
biochemical recurrence when the PPF was higher or
lower than 50% respectively.
However, most studies assessing the prognos-
tic value of PPF have limitations. All of them involve
at least 2 centers and, thus, surgical procedures and
pathological analyses were performed by a heteroge-
neous group of professionals. Moreover, they have a
limited follow-up with a median of 38.5 months
(maximum 46 months), and finally, they do not show
an agreement concerning the ideal cut-off points that
should be considered when analyzing the PPF (11-
14).
The objective of this study is to assess the
prognostic value of PPF for biochemical recurrence
in patients with low-grade PCa undergoing radical
prostatectomy.
MATERIALS AND METHODS
From March 1991 to November 2000, we
selected 440 patients with localized prostate cancer
undergoing radical prostatectomy at our institution.
When selecting this group, those cases receiving
neoadjuvant or adjuvant hormone therapy (14 pa-
tients), and adjuvant radiotherapy (1 patient) were
excluded, as were cases presenting Gleason score
higher than 6 at biopsy; thus, the inclusion criterion
was a Gleason score <  6 at biopsy. All surgical pro-
cedures were performed by the same surgeon and
pathology analyses by the same pathologist.
During staging, all patients underwent anam-
nesis and physical examination, dosing alkaline phos-
phatase, total and prostatic acid phosphatase, serum
PSA, pelvic computerized tomography and bone scin-
tigraphy, aiming to rule out any signs of extraprostatic
disease. Diagnoses were made through transrectal
biopsy of the prostate motivated by increases in se-
rum PSA or changes in the digital rectal examina-
tion. Postoperatively, patients were assessed every 2
months for 1 year, then every 6 months for 5 years,
and then yearly. During each assessment, patients
underwent digital rectal examination of the prostate
cavity and analysis of serum PSA. Imaging studies
were repeated every year. Biochemical progression
was defined as a serum PSA higher or equal to 0.4
ng/mL, a cut-off value also instituted by other au-
thors (15). Median follow-up was 60 months (2 –
130.5 m). Only four patients (0.9%) were lost during
follow-up. The patients’ mean age was 62.5 ± 7.4
years, ranging from 40 to 79 years.
Clinical staging was defined according to the
AJCC classification, 1992 (16), and histological grade
according to the Gleason score (17). Serum PSA was
divided into categories from 0 to 4 ng/mL, 4.1 to 10
ng/mL, 10.1 to 20 ng/mL and higher than 20 ng/mL.
The PPF was defined as the total number of fragments
with cancer divided by the total number of fragments
in biopsy times 100. This variable was divided into
categories from 0 to 25%, 25.1% to 50%, 50.1 to 75%
and 75% to 100%.
The patient distribution according to clinical
staging is listed on Table-1. Tables-2, 3 and 4 stratify
patients according to pre-operative PSA, PPF and the
pathological stage of the surgical specimen respec-
tively.
A survival analysis approach was used for the
statistical analysis considering a biochemical recur-
rence of the disease as the event of interest. This was
defined by a PSA value higher or equal to 0.4 ng/mL.
For disease-free survival curves, the Kaplan-Meier
method and the log-rank test were used for compar-
ing the curves of percentage of affected fragments.
On the multivariate analysis, a Cox proportional-haz-
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ards regression model was adjusted. The assumption
of proportional risks in the adopted model was
checked by construction log-minus-log graphs, which
did not indicate violation of the proportional hazard
assumption. P values p < 0.05 were considered statis-
tically significant.
RESULTS
During a median follow-up period of 60
months (2 – 130.5 m), 109 (24.8%) of the 440 pa-
tients under study presented biochemical recurrence.
Figure-1 shows the mean disease-free survival time
estimated at 97 months with 95% confidence inter-
val. We can observe that at 116 months, the likeli-
hood of a patient being disease-free was approxi-
mately 50.7%.
The number of biopsied fragments ranged
from 2 to 19, with means and medians of 7.01 and
6.0 fragments respectively, with 40.6% of fragments
affected by cancer.
On the univariate analysis, Table-5 shows the
patient distribution according to the cut-off points for
PPF and the probability of biochemical recurrence.
We can observe that more than one half of patients
presenting PPF > 75% had biochemical recurrence.
Figure-2 shows the disease-free survival curves in re-
lation to PPF according to predefined cut-off points.
We observe that PPF significantly influenced disease-
free survival (log-rank, p < 0.001).
After Cox regression analysis to control for
pre-operative serum PSA, we observed that both se-
rum PSA and PPF were independent predictive fac-
Clinical Staging                                N. of Patients
T1C 206 (46.8%)
T2A 122 (27.7%)
T2B 093 (21.1%)
T2C 017 (3.9%)
T3A 002 (0.5%)
Total 440 (100%)
Table 1 – Patient distribution according to clinical stag-
ing (AJCC, 1992).
Table 3  –  Patient distribution according to the percent-
age of positive fragments (PPF) at pre-operative biopsy.
PPF               N. of  Patients
0 to 25% 149
25.1 to 50% 197
50.1 to 75%  53
75.1 to 100%  41
Table 2 – Patient distribution according to pre-operative
PSA levels.
PSA Levels                                        N.  of  Patients
0 to 4 043 (10%)
4.1 to 10 234 (53%)
10.1 to 20 123 (28%)
> 20 040 (9%)
Table 4  –  Patient distribution according to pathological
stage.
Pathological  Stage                           N. of Patients
T2A 137 (31.1%)
T2A, NX 002 (0.5%)
T2B 118 (26.8%)
T2B, NX 003 (0.7%)
T2C 085 (19.3%)
T3A 067 (15.2%)
T3B 006 (1.4%)
T3C 022 (5%)
Total 440 (100%)
Table 5 –  Relationship between the percentage of positive
fragments (PPF) at pre-operative biopsy and the number
of biochemical recurrences.
PPF   N. of  Biochemical
       Recurrences
0 to 25% 23 (15%)
25.1 to 50% 47 (24%)
50.1 to 75% 17 (32%)
75.1 to 100% 22 (54%)
p < 0.001
37
 POSITIVE FRAGMENTS IN PROSTATE BIOPSY
Figure 1 – Probability curve of disease-free survival.
Figure 2  –  Probability curve of disease-free survival according to the percentage of positive fragments (PPF) at pre-operative biopsy.
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tors for disease-free survival in the post-operative
period (Table-6).
COMMENTS
This study demonstrated that the PPF at bi-
opsy could influence postoperative biochemical re-
currence in patients with Gleason scores between 2
and 6 undergoing definitive treatment by radical pros-
tatectomy. Thus, patients who have 0 to 25% and more
than 75% of fragments affected present 15% and 54%
of biochemical recurrences respectively. Additionally,
in the multivariate analysis controlling for pre-opera-
tive serum PSA, the PPF at biopsy was the strongest
predictive factor for determining biochemical recur-
rence, adding prognostic information in the group of
patients under study.
Pathological data obtained from prostate bi-
opsies have been poorly explored. In clinical prac-
tice, we can observe that information obtained only
through pre-operative analysis of serum PSA, the
biopsy’s Gleason scores and clinical staging are of-
ten insufficient to predict the pathological staging of
the surgical specimen and the disease-free survival
in patients undergoing definitive treatment by radi-
cal prostatectomy (3).
In this context, several studies have demon-
strated that PPF provides additional information for
the post-operative pathological findings and clinical
features of patients undergoing radical prostatectomy.
One analysis of 104 patients with a mean age of 61
found a significant association between the number
of affected fragments by prostate lob on the sextant
biopsy and an extracapsular extension of PCa. Thus,
extracapsular extension occurred in 9%, 12%, 32%
and 40% of the sides presenting zero, 1, 2 and 3 of 3
fragments affected respectively (5). Other authors
observed that the probability of metastases in pelvic
lymph nodes was 5% and 30% when 3 and 6 frag-
ments were affected respectively. They also observed
a higher incidence of Gleason scores 4 and 5 with the
increased number of affected fragments. As for lo-
gistic regression analysis, this was the best predic-
tive factor for lymph nodal status (6). Finally,
Gancarczyk et al. (8), in studies about the prognostic
value of PPF at biopsy for determining the post-op-
erative pathological staging in 1510 patients from the
Center for Prostate Disease Research through uni- and
multivariate analysis, divided the PPF into 3 catego-
ries: less than 30%, from 30 to 59% and equal to or
higher than 60%. The authors observed that the PPF
combined with the pre-operative serum PSA and
Gleason scores at biopsy were the most important
predictive factors for the pathological staging of the
surgical specimen. Based on these findings, they in-
cluded the PPF in a probability nomogram for pre-
dicting post-operative pathological findings in such
patients.
PPF has also been used for predicting the
post-operative biochemical progression in patients
Table 6  –  Analysis of relative risk for PSA and percentage of positive fragments (PPF) in the Cox regression model.
Variable
PSA
(4.1 to 10 / 0 to 4)
(10.1 to 20 / 0 to 4)
(> 20 / 0 to 4)
PPF
(25.1 to 50% / 0 to 25%)
(50.1 to 75% / 0 to 25%)
(75.1 to 100% / 0 to 25%)
2.22
3.83
6.17
1.35
1.65
3
 95% C.I.
[0.79 ; 6.22]
[1.36 ; 10.74]
[2.09 ; 18.21]
[0.82 ; 2.23]
[0.88 ; 3.10]
[1.65 ; 5.45]
0.128
0.011
0.001
0.234
0.122
< 0.001
Relative Risk p-value
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undergoing radical prostatectomy. A retrospective
study of 1094 patients from 4 institutions in the
SEARCH database who were treated by radical pros-
tatectomy defined that the PPF was an independent
prognostic variable for determining post-operative
pathological findings and biochemical recurrences.
The study used 3 cut-off points for PPF – less than
34%, 34 to 50% and more than 50% – and when the
study population was divided into risk groups based
on the classic parameters (serum PSA, Gleason scores
at biopsy and clinical staging), PPF provided addi-
tional prognostic information for patients with low
and moderate risk, but did not add any information
for the high-risk group (12).
Subsequently, this same group compared the
ability of predicting biochemical recurrence in the PPF
of the entire gland with the PPF of the lobe that was
most affected by PCa (13). With a mean follow-up of
27 months, this multivariate analysis showed that the
PPF of the dominant side was the strongest predictive
factor for post-operative biochemical recurrence. Thus,
it would be worse for a patient to have 80% positive
fragments in one lobe and 0% in the other, than to have
40% positive fragments in each lobe.
More recently, Lotan et al. (14), found a
strong association between PPF and the tumor stage,
histological differentiation, biochemical progression,
distant metastases and overall survival. After assess-
ing 630 patients with mean age of 60.4 years and mean
pre-operative PSA of 8.1 ng/mL who were followed
for 21.2 months after radical prostatectomy, 13% of
the patients presented disease progression. Patients
with a PPF higher than 25% had their disease-free
survival estimated at 70% versus 90% when the PPF
was lower or equal to 25%. PPF was associated with
biochemical recurrence on the pre- and post-opera-
tive multivariate analysis.
However, despite all these results, the most
accurate method for quantifying tumor volume in the
prostate biopsy is still grounds for debate. Some stud-
ies have shown that more detailed analyses of pros-
tate biopsies, such as the total percentage of cancer-
ous tissue or a higher percentage of cancer in one
affected fragment, are the most adequate methods for
measuring tumor volume in prostate biopsies (18,19).
In the series from Freedland et al. (18), the percent-
age of cancerous tissue at biopsy was a stronger pre-
dictive factor for post-operative biochemical recur-
rence than PSA and Gleason scores at biopsy. It was
also predictive of the involvement of seminal vesicle
and extraprostatic disease. On the other hand, the
measurement of tumor volume through these meth-
ods is more laborious and not all pathologists pro-
vide this information. The PPF measurement as per-
formed in this study seems to be easier and more prac-
tical. Additionally, there is research showing that PPF
was a stronger predictive factor for biochemical re-
currence than the total percentage of tissue affected
by carcinoma at biopsy, and the latter did not add any
prognostic information to the former in patients from
the intermediary-risk group (20,21). In fact, the best
method for estimating tumor volume through biopsy
still has to be established by controlled studies com-
paring these methods.
A limiting factor in series presented so far is
the short follow-up period. With the present study, prog-
nostic data highlighted in the worldwide literature were
ratified, with a median follow-up of 5 years, adding at
least 14 months to the follow-up period in the longer
series. Additionally, new cut-off points were defined
for PPF that were shown to present statistical signifi-
cance, which, therefore, can be employed in clini-
cal practice. Since the categories of 25.1% to 50%,
and 50.1% to 75% had similar disease-free survival
curves (Figure-2) and did not present statistical dif-
ference when compared to the category from 0 to
25% (Table-5, p > 0.122), in practical terms the cut-
off points could be divided into lower than 25%, 25.1%
to 75% and higher than 75%. Finally, the authors em-
phasize that the PPF measurement at biopsy is a simple
and practical method that should be routinely used as
a predictive factor for biochemical recurrence in pa-
tients with PCa who have Gleason scores from 2 to 6.
Adriana Sanudo performed the statistical analysis
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